# Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma

> **NCT00499577** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Maryland Greenebaum Cancer Center** · enrollment: 56 (estimated)

## Conditions studied

- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **BIOLOGICAL:** CMV pp65 peptide
- **BIOLOGICAL:** hTERT I540/R572Y/D988Y multipeptide vaccine
- **BIOLOGICAL:** pneumococcal polyvalent vaccine
- **BIOLOGICAL:** survivin Sur1M2 peptide vaccine

## Key facts

- **NCT ID:** NCT00499577
- **Lead sponsor:** University of Maryland Greenebaum Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2009-02
- **Final completion:** —
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2014-01-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00499577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00499577, "Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00499577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*